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A B S T R A C T
Background: Initial studies have shown that old occlusions or those with indeterminate occlusion duration 
have been associated with percutaneous coronary intervention (PCI) failure and a worse prognosis. This 
study aimed to determine the impact of occlusion duration on the success and outcomes of contemporary 
PCI on chronic total occlusion (CTO). 
Methods: The authors analyzed a retrospective cohort of consecutive patients submitted to PCI in CTO, 
who were compared according to the confirmed occlusion duration (COD) < 12 months, ≥ 12 months, or 
indeterminate occlusion duration (IOD). 
Results: A total of 168 patients were treated, 122 (72.6%) with COD (80 < 12 months, 42 ≥ 12 months) and 46 
(24.7%) with an IOD. Lesion extension was 17.0 ± 13.6 mm, in 2.90 ± 0.58 mm vessels, and the anterograde 
approach was used in 98.8% of cases. Angiographic success was attained in 79.2% of patients (80.0% vs. 73.8% 
vs. 82.6%; p = 0.73). The main cause of failure was the inability to cross the lesion with the guidewire (68.6%). 
Occlusion duration had no impact on in-hospital events (4.8% vs. 7.1% vs. 6.0%; p = 0.73), which were almost 
entirely explained by periprocedural myocardial infarction, or on late outcomes (18.8% vs. 7.1% vs. 15.3%; 
p = 0.23). At the multivariate analysis, lesion length ≥ 20 mm (odds ratio - OR = 7.27; 95% confidence interval 
- 95% IC 1.94-29.1; p = 0.003), calcification (OR = 4.72; 95% CI 1.19-19.1; p = 0.02), and tortuosity of the 
occluded segment (OR = 15.98; 95% CI 2.18-144.7; p = 0.007) were predictors of failure. 
Conclusions: Occlusion duration was not associated with increased failure rate of the procedure or worse 
PCI outcomes in CTO. 
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Impacto do tempo de oclusão na taxa de sucesso e nos resultados da intervenção 
coronária percutânea em obstruções totais crônicas
R E S U M O
Introdução: Estudos iniciais mostram que oclusões antigas ou com tempo indeterminado têm sido 
associadas a insucesso da intervenção coronária percutânea (ICP) e a pior prognóstico. Nosso objetivo foi 
determinar o impacto do tempo de oclusão no sucesso e nos resultados da ICP contemporânea na obstrução 
total crônica (OTC). 
Métodos: Analisamos uma coorte retrospectiva de pacientes consecutivos que realizaram ICP em OTC, e 
que foram comparados de acordo com o tempo de oclusão confirmado (TOC) < 12 meses, ≥ 12 meses, ou 
indeterminado (TOI). 
Resultados: Foram tratados 168 pacientes, 122 (72,6%) com TOC (80 < 12 meses, 42 ≥ 12 meses) e 46 
(24,7%) com TOI. A extensão da lesão foi de 17,0 ± 13,6 mm, em vasos de 2,90 ± 0,58 mm, e a abordagem 
anterógrada foi utilizada em 98,8% dos casos. Sucesso angiográfico foi obtido em 79,2% dos pacientes 
(80,0% vs. 73,8% vs. 82,6%; p = 0,73). A principal causa de insucesso foi a incapacidade de cruzar a lesão com 
o fio-guia (68,6%). O tempo de oclusão não teve impacto na taxa de eventos cardiovasculares hospitalares 
(4,8% vs. 7,1% vs. 6,0%; p = 0,73), explicados em sua quase totalidade pelos infartos do miocárdio 
periprocedimento, ou nos eventos tardios (18,8% vs. 7,1% vs. 15,3%; p = 0,23). Na análise multivariada, 
comprimento da lesão ≥ 20 mm (odds ratio - OR = 7,27; intervalo de confiança de 95% - IC 95% 1,94-
29,1; p = 0,003), calcificação (OR = 4,72; IC 95% 1,19-19,1; p = 0,02) e tortuosidade do segmento ocluído 
(OR = 15,98; IC 95% 2,18-144,7; p = 0,007) foram preditores de insucesso. 
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Conclusões: O tempo de oclusão não está associado ao aumento da taxa de insucesso do procedimento ou a 
piores resultados da ICP em OTC.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Chronic total occlusion (CTO) is found in approximately 15 to 30% 
of patients referred for elective coronary angiography.1 However, 
percutaneous coronary intervention (PCI) for CTO corresponds to 
only 10% of the total procedures2,3 and remains one of the most chal-
lenging interventions in the field. In fact, the number of percuta-
neous procedures in CTO has remained stable in recent years,4 
despite the development of new techniques such as the retrograde 
approach, the use of new dedicated devices, and the increased expe-
rience of interventionists, resulting in increasingly higher success 
rates.5-8 It is known that a myocardial area irrigated by an occluded 
artery may be associated with persistent ischemia, even in the pre-
sence of well-developed collaterals,9 and that the successful revas-
cularization of the lesion is associated with reduced ischemic 
burden and improved ventricular contractility.10 Studies have shown 
the improvement in late prognosis of patients submitted to success-
ful PCI compared to those with procedural failure.11-14 The main rea-
son for this failure is the inability to cross the lesion with the 
guidewire or the balloon. Initial studies have shown that a long oc-
clusion duration is associated with failure of the technique.15,16 Simi-
larly, an indeterminate occlusion duration (IOD) is also associated 
with PCI failure.17 Conversely, a more recent study showed no asso-
ciation between the occlusion duration and the success rate of the 
procedure.18
The aim of this study was to determine the impact of occlusion 
duration on the success and outcomes of contemporary PCI in CTO.
Methods
Study population
A retrospective cohort of consecutive patients submitted to PCI 
in occlusive lesions was assessed from June 2008 to December 2014 
in a tertiary cardiology reference hospital linked to the Brazilian 
Unified Health System (SUS, acronym in Portuguese). After the re-
view of medical records and analysis of coronary angiography, pa-
tients who had estimated occlusion duration < 3 months or 
antegrade coronary flow, with Thrombolysis in Myocardial Infarc-
tion (TIMI) > 0, were excluded.
Definitions
CTO was defined as TIMI grade 0 flow in the occluded segment, 
with estimated occlusion duration > 3 months.19,20 The levels of cer-
tainty of occlusion duration followed the definitions of the European 
Consensus Euro CTO Club:19 confirmed occlusion duration (COD) in 
patients with angiographic evidence of occlusion > 3 months or ob-
jective evidence of acute myocardial infarction (AMI) in the occlu-
ded coronary > 3 months before the coronary angiography; or IOD in 
patients with coronary occlusion with TIMI grade zero flow and ana-
tomy suggestive of long-term occlusion (presence of collaterals or 
absence of contrast retention) with ischemic symptoms unaltered in 
the last 3 months or evidence of silent ischemia. 
Collateral circulation was classified according to Rentrop et al.:21 
grade 0, if there was no visible collateral filling; grade 1, if there was 
filling of lateral branches of the infarct-related artery, without rea-
ching the epicardial segment; grade 2, if there was partial filling of 
the epicardial vessel; and grade 3, if there was complete filling of the 
collateral vessel promoted by the collaterals.
Angiographic success was defined as final residual stenosis 
< 20% with distal TIMI 3 flow. AMI was defined as an increase in 
creatine kinase MB isoenzyme (CK-MB) > 3 times the upper limit of 
normal, associated with electrocardiographic findings and/or 
symptoms suggestive of ischemia (periprocedural AMI) or increa-
sed CK-MB or troponin levels above the 99th percentile of a referen-
ce control population (spontaneous AMI). New target vessel 
revascularization (TVR) was defined as repeat PCI or bypass graft 
placement for restenosis at the lesion treated during index PCI due 
to symptoms and/or functional tests, with demonstration of ische-
mia in the corresponding territory. Contrast-induced nephropathy 
was defined as an absolute increase in serum creatinine level of 0.5 
mg/dL or a 25% increase compared to basal level within 48 hours of 
the procedure.22
Procedure
PCI was performed according to standardized techniques.19,20 
The procedure was indicated for patients with angina or ischemic 
equivalent and/or ischemia proven in functional tests, being electi-
ve in all cases. All patients received acetylsalicylic acid (loading 
dose of 200 mg and maintenance dose of 100 mg daily) and clopi-
dogrel (loading dose of 300 mg and maintenance dose of 75 mg 
daily). Unfractionated heparin, at a dose of 100 U/kg, was used to 
maintain an activated clotting duration > 250 seconds throughout 
the procedure. The use of glycoprotein IIb/IIIa inhibitors during the 
procedure was at the discretion of the interventionist, as well as 
the selection of access route and type of stent. Low-osmolality io-
nic contrast medium (ioxaglate) was used in all cases, and patients 
with clearance < 60 mL/minute received isotonic (0.9%) saline for at 
least 6 hours before and 12 hours after the intervention. Acetylsa-
licylic acid was maintained indefinitely and clopidogrel was main-
tained for at least 1 month after bare-metal stents, or 12 months 
after acute coronary syndrome or when a drug-eluting stent was 
implanted.
Analyzed outcomes 
The primary objective was to evaluate the success rate of the pro-
cedure, according to the estimated occlusion duration. The patients 
were divided into three groups for analysis: < 12 months, ≥ 12 mon-
ths, or indeterminate. The analyzed secondary outcomes included 
in-hospital  complications and combined major adverse cardiovas-
cular events (MACE), defined as occurrence of death from all causes, 
AMI, or new TVR, both in-hospital and at the follow-up. Additionally, 
the authors analyzed MACE at the end of follow-up, according to 
procedural success or failure. 
Coronary angiography was reviewed by two independent inter-
ventional cardiologists to determine the anatomical characteristics 
of lesions and vessels using QAngio® XA software, version 7.3 (Medis 
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Medical Imaging Systems BV, Leiden, the Netherlands) for the quan-
titative angiography analysis.
Statistical analysis
Continuous variables are shown as mean ± standard deviation or 
median and interquartile range, and compared using analysis of va-
riance (ANOVA) or Kruskal-Wallis test, when they showed non-nor-
mal distribution. Categorical variables are shown as absolute 
numbers and percentages and compared using the chi-squared test 
or Fisher's exact test, as appropriate. The cumulative probability of 
MACE was obtained using Kaplan-Meier curves and the difference 
between groups was calculated by the log-rank test.
Predictors of angiographic failure were identified using binary lo-
gistic regression, including the following variables: diabetes mellitus, 
chronic renal failure, left ventricular dysfunction, multivessel coro-
nary disease, tortuosity in the occlusion segment, presence of calcifi-
cation, blunt stump, presence of bridge collaterals, presence of lateral 
branch at the site of occlusion, occlusion length ≥ 20 mm, vessel dia-
meter ≤ 2.5 mm, ostial location, occluded coronary artery, and esti-
mated occlusion duration. Variables that showed p < 0.10 in the 
univariate analysis were used in the multivariate model. 
Two-tailed p-values < 0.05 were considered statistically signifi-
cant. Analyses were performed using the R software, version 3.1 
(The R Foundation for Statistical Computing, 2014, Vienna, Austria).
Results
Of the 328 analyzed patients with occlusive lesions, 168 met the 
criteria established for COD > 3 months and were selected. A total 
of 122 patients (72.6%) met the definitions for COD, of whom 80 
had duration < 12 months and 42 ≥ 12 months, whereas 46 (27.4%) 
met the definitions for IOD. The occlusion duration in the group 
with COD showed a median of 6.0 months (interquartile range: 4.0 
to 12.0 months) and ranged from 3 to 144 months (Fig. 1A). The 
mean age of the population was 59.2 ± 9.5 years, with a predomi-
nance of males (70.2%), presence of diabetes mellitus in 29.8% of 
patients, and 18.5% had chronic renal failure.
Patients with COD ≥ 12 months had a higher prevalence of smoking 
and chronic renal failure, whereas patients in the group with COD < 12 
months had lower prevalence of previous PCI. Most patients were re-
ceiving drug therapy for stable coronary disease, with a higher rate of 
vasodilators in the group with COD ≥ 12 months (Table 1).  
The most commonly treated artery was the left anterior descen-
ding artery (42.3%), followed by the right coronary artery (41.1%) 
and the left circumflex artery (Table 2). No significant difference 
was observed between groups regarding patients’ angiographic 
characteristics, except in the distribution of lesion location (p = 
0.02), although there was no difference regarding the ostial loca-
tion of lesions. Multivessel coronary artery disease was present in 
44.6% of patients. The lesions had an occlusive segment on average 
17.0 ± 13.6 mm long in vessels of 2.90 ± 0.58 mm in diameter. Colla-
teral circulation grade 2 or 3 was present in approximately 90% of 
patients.
As for the procedural data (Table 3), the 6 F sheath was used in 
94.6% of cases and the femoral access, in 58.9%. The antegrade 
approach was used in most cases (98.8%). A total of 152 stents was 
implanted in 133 patients, with a mean of 1.2 ± 0.8 stents implanted 
per lesion, with no significant difference between the groups. The 
most often used stent was the drug-eluting stent, especially in the 
groups with COD ≥ 12 months (89.7%; p < 0.001). During the proce-
dure, 124.2 ± 61.2 mL of contrast were used, with use of larger volu-
mes in the group with COD ≥ 12 months, when compared with the 
group with COD < 12 months and IOD (117.2 mL vs. 144.2 mL vs. 
118.3 mL; p = 0.02). The main cause of procedural failure was the 
inability to cross the lesion with the guidewire (68.6%). 
Angiographic success was achieved in 79.2% of cases, with no 
significant difference between groups (80.0% vs. 73.8% vs. 82.6%; 
p = 0.73; Fig. 1B). Regarding in-hospital complications, there was 
no significant difference between the groups regarding MACE 
(4.8% vs. 7.1% vs. 6.0%; p = 0.73), which was explained almost enti-
rely by periprocedural AMI. There were no deaths and only one 
TVR was observed due to a stent thrombosis that occurred hours 
after the procedure. There were three coronary perforations, 
Figure 1. (A) Number of patients with chronic total occlusions, according to the occlusion duration. (B) Angiographic success rate, according to the estimated occlusion duration. 
PCI: percutaneous coronary intervention.
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Table 1
Clinical and demographic characteristics.
COD (n = 122)
Characteristic Total
(n = 168)
< 12 months
(n = 80)
≥ 12 months
(n = 42)
IOD (n = 46) p-value
Age, years 59.2 ± 9.5 58.9 ± 8.9 60.4 ± 9.7 60.9 ± 10.1 0.24
Male gender, n (%) 118 (70.2) 52 (65.0) 31 (73.8) 35 (76.1) 0.35
Diabetes mellitus, n (%) 50 (29.8) 25 (31.2) 16 (38.1) 9 (19.6) 0.15
Arterial hypertension, n (%) 148 (88.1) 71 (88.7) 38 (90.5) 39 (84.8) 0.69
Dyslipidemia, n (%) 123 (73.2) 59 (73.8) 33 (78.6) 31 (67.4) 0.49
Smoking, n (%) 87 (51.8) 38 (47.5) 29 (69.0) 20 (43.5) 0.03
Chronic renal failure, n (%) 31 (18.5) 7 (8.7) 14 (33.3) 10 (21.7) 0.003
Previous PCI, n (%) 19 (11.3) 4 (5.0) 7 (16.7) 8 (17.4) 0.04
Left ventricular dysfunction, n (%) 35 (20.8) 23 (28.7) 6 (14.3) 6 (13.0) 0.054
Clinical presentation, n (%) 0.003
Asymptomatic 52 (31.0) 21 (26.3) 8 (19.0) 23 (50.0)
Stable angina 116 (69.0) 59 (73.8) 34 (81.0) 23 (50.0)
Medication, n (%)
Acetylsalicylic acid 167 (99.4) 79 (98.8) 42 (100) 46 (100) 0.57
Beta-blocker 139 (82.7) 68 (85.0) 38 (90.5) 33 (71.7) 0.051
ACEI/ARB 151 (89.9) 75 (93.8) 35 (83.3) 41 (89.1) 0.18
Statin 161 (95.8) 79 (98.8) 38 (90.5) 44 (95.7) 0.09
Vasodilator 35 (20.8) 13 (16.3) 16 (38.1) 6 (13.0) 0.005
COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; PCI: percutaneous coronary intervention; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.
Table 2
Angiographic characteristics. 
COD (n = 122)
Characteristic Total
(n = 168)
< 12 months
(n = 80)
≥ 12 months
(n = 42)
IOD (n = 46) p-value
Artery with CTO, n (%) 0.62
Left anterior descending artery 71 (42.3) 37 (46.3) 18 (42.9) 16 (34.8)
Left circumflex artery 28 (16.7) 14 (17.5) 5 (11.9) 9 (19.6)
Right coronary artery 69 (41.1) 29 (36.2) 19 (45.2) 21 (45.7)
Number of diseased vesselsa, n (%) 0.36
1 93 (55.4) 46 (57.5) 24 (57.1) 23 (50.0)
2 62 (36.9) 30 (37.5) 16 (38.1) 16 (34.8)
3 13 (7.7) 4 (5.0) 2 (4.8) 7 (15.2)
Lesion lengthb, mm 17.0 ± 13.6 15.8 ± 12.4 23.9 ± 19.9 16.7 ± 13.0 0.35
Lesion ≥ 20 mm, n (%) 21 (18.1) 11 (17.7) 3 (25.0) 7 (16.7) 0.78
Vessel diameterb, mm 2.90 ± 0.58 2.85 ± 0.52 2.93 ± 0.71 2.96 ± 0.63 0.76
Vessel ≤ 2.5 mm, n (%) 30 (25.9) 15 (24.2) 3 (25.0) 12 (28.6) 0.90
Vessel ≥ 3.5 mm, n (%) 19 (16.4) 8 (12.9) 3 (25.0) 8 (19.0) 0.43
Calcificationb, n (%) 24 (20.7) 11 (17.7) 6 (50.0) 7 (16.7) 0.04
Blunt stump morphologyb, n (%) 26 (22.4) 16 (25.8) 2 (16.7) 8 (19.0) 0.71
Lesion location, n (%) 0.02
Ostial 19 (11.3) 8 (10.0) 5 (11.9) 6 (13.0)
Proximal 53 (31.5) 24 (30.0) 13 (31.0) 16 (34.8)
Medial 85 (50.6) 48 (60.0) 20 (47.6) 17 (37.0)
Distal 11 (6.5) 0 (0.0) 4 (9.5) 7 (15.2)
Lesion tortuosityb, n (%) 8 (6.9) 4 (6.5) 0 (0.0) 4 (9.5) 0.65
Collateral circulationb, n (%) 0.86
Grade 2 18 (15.5) 11 (17.7) 2 (16.7) 5 (11.9)
Grade 3 84 (72.4) 43 (69.4) 8 (66.7) 33 (78.6)
Bridge collateralsb, n (%) 37 (31.9) 18 (29.0) 3 (25.0) 16 (38.1) 0.59
Lateral branchb, n (%) 42 (36.2) 24 (38.7) 3 (25.0) 15 (35.7) 0.72
COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; CTO: chronic total occlusion. 
a With luminal reduction ≥ 70% at angiography. 
b Angiographic characteristics available in 116 patients. 
none of which required pericardiocentesis. Contrast-induced 
nephropathy rates (8.7% vs. 2.4% vs. 13.0%; p = 0.19) did not differ 
between the groups.  
The median clinical follow-up was 21.3 months (interquartile range: 
5.9 to 36.5 months). There was no significant difference between groups at 
the end of follow-up regarding rates of MACE (18.8% vs. 7.1% vs. 15.3%; 
p = 0.23), death (3.7% vs. 0 % vs. 4.3%; p = 0.59), AMI (7.5% vs. 4.8% vs. 8.7%; 
p = 0.86), or new TVR (11.2% vs. 2.4% vs. 6.5%; p = 0.23; Table 4 and Fig. 2A). 
Similarly, there was no significant difference in the cumulative rate of 
MACE at the end of follow-up between patients who had a successful PCI 
and those who did not (21.8% vs. 20.7%; hazard ratio - HD = 1.41; 95% confi-
dence interval - 95% CI 0.42-4.18, log-rank p = 0.41; Fig. 2B).
Predictors associated with angiographic failure in the univariate 
model were lesion length ≥ 20 mm, reference vessel diameter ≤ 2.5 mm, 
calcified lesion, multivessel coronary disease, presence of tortuosity 
in the occluded segment, and chronic renal failure. Of these, lesion 
length ≥ 20 mm (OR = 7.27; 95% CI 1.94-29.1; p = 0.003), presence of 
calcification (OR = 4.72; 95% CI 1.19-19.1; p = 0.02), and tortuosity in 
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Table 3
Characteristics of procedure.
COD (n = 122)
Characteristic Total
(n = 168)
< 12 months
(n = 80)
≥ 12 months
(n = 42)
IOD (n = 46) p-value
Angiographic success, n (%) 133 (79.2) 64 (80.0) 31 (73.8) 39 (82.6) 0.57
Cause of failurea, n (%) 0.09
Guidewire did not cross the lesion 24 (68.6) 12 (75.0) 9 (81.8) 3 (37.5)
Coronary perforation 3 (8.6) 0 (0.0) 1 (9.1) 2 (25.0)
Residual lesion 4 (11.4) 2 (12.5) 0 (0.0) 2 (25.0)
Other 4 (11.4) 2 (12.5) 1 (9.1) 1 (12.5)
Sheath, n (%) 0.67
6 F 159 (94.6) 77 (96.3) 39 (92.9) 43 (93.5)
7 F 9 (5.4%) 3 (3.7) 3 (7.1) 3 (6.5)
Type of access, n (%) 0.60
Femoral 99 (58.9) 49 (61.2) 22 (52.4) 28 (60.9)
Radial 69 (41.1) 31 (38.8) 20 (47.6) 18 (39.1)
Number of implanted stents per treated 
vesselb
1.2 ± 0.8 1.3 ± 0.8 1.1 ± 1.0 1.0 ± 0.5 0.30
Stent lengthb, mm 31.3 ± 18.0 32.4 ± 18.2 30.3 ± 22.7 30.5 ± 11.9 0.85
Stent diameterb, mm 3.7 ± 2.0 4.0 ± 2.1 3.6 ± 2.4 3.5 ± 1.3 0.51
Contrast volume, mL 124.2 ± 61.2 117.2 ± 58.5 144.2 ± 64.6 118.3 ± 59.9 0.02
Stent typeb, n (%) < 0.001
Drug-eluting stent 91 (59.9) 34 (47.9) 35 (89.7) 22 (52.4)
Bare metal stent 61 (40.1) 37 (52.1) 4 (10.3) 20 (47.6)
COD: confirmed occlusion duration; IOD: indeterminate occlusion duration. 
a Relating to total of 35 interventions without success. 
b Total of 152 implanted stents. 
Table 4
In-hospital and late clinical outcomes.
COD (n = 122)
Clinical outcome Total
(n = 168)
< 12 months
(n = 80)
≥ 12 months
(n = 42)
IOD (n = 46) p-value
In-hospital outcomes 
MACE, n (%) 8 (4.8) 4 (5.0) 1 (2.4) 3 (6.5) 0.73
Death, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) NA
AMI, n (%) 8 (4.8) 4 (5.0) 1 (2.4) 3 (6.5) 0.73
Target vessel revascularization, n (%) 1 (0.6) 1 (1.2) 0 (0.0) 0 (0.0) 0.99
Contrast-induced nephropathy, n (%) 14 (8.3) 7 (8.7) 1 (2.4) 6 (13.0) 0.19
Late outcomes
MACE, n (%) 25 (14.9) 15 (18.8) 3 (7.1) 7 (15.2) 0.23
Death, n (%) 5 (3.0) 3 (3.7) 0 (0.0) 2 (4.3) 0.59
AMI, n (%) 12 (7.1) 6 (7.5) 2 (4.8) 4 (8.7) 0.86
Target vessel revascularization, n (%) 13 (7.7) 9 (11.2) 1 (2.4) 3 (6.5) 0.23
COD: confirmed occlusion duration; IOD: indeterminate occlusion duration; MACE: major adverse cardiovascular events; NA: not applicable; AMI: acute myocardial infarction.
patients with coronary lesions with CTO using the antegrade appro-
ach, which is comparable to those found in other recent large stu-
dies.23-26 Additionally, this study showed that PCI in CTO is a safe 
procedure with a low rate of in-hospital complications, no deaths, 
and no need for emergency coronary artery bypass surgery or car-
diac tamponade requiring pericardial drainage during in-hospital 
stay, a finding similar to that of previous studies.17,27,28
The main finding of this study was that neither a long occlu-
sion duration nor IOD affected the success rate or the long-term 
prognosis of patients undergoing PCI in CTO. The analysis of ini-
tial studies showed an association between long occlusion dura-
tion and angiographic failure of the procedure.15,16 More recently, 
Olivari et al. showed that occlusion duration superior to 6 mon-
ths was associated with percutaneous intervention failure in an 
analysis of 376 consecutive patients with CTO, although, in that 
study, not all patients had occlusion duration superior to 3 mon-
ths.29 Similarly, Barlis at al. demonstrated that an IOD determines 
a five-fold increase in the risk of angiographic failure in an analy-
sis of 202 patients undergoing PCI in CTO.17 Currently, with the 
increased experience of interventionists and the development 
and improvement of new devices, the occlusion duration has 
Table 5
Independent predictors of angiographic failure.
Variable OR 95% CI p-value
Lesion length ≥ 20 mm 7.14 1.90-28.70 0.004
Vessel diameter ≤ 2.5 mm 3.27 0.88-12.21 0.07
Presence of calcification 4.53 1.10-18.83 0.03
Multivessel coronary disease 2.66 0.99-7.79 0.056
Lesion tortuosity 16.33 2.22-149.4 0.02
Chronic renal failure 0.84 0.10-5.46 0.86
Occlusion duration (months) 1.47 0.14-2.46 0.72
Hosmer-Lemeshow statistics = 0.14.  
OR: odds ratio; 95% CI: 95% confidence interval.
the occluded segment (OR = 15.98; 95% CI 2.18-144.7; p = 0.007) were 
independent predictors of angiographic failure in the multivariate 
model (Table 5). 
Discussion
The present study has several important findings. First, a success 
rate of 79.2% in PCI was identified in a selection of contemporary 
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Indeterminate
< 12 months
≥ 12 months
Number at risk
Indeterminate 46
< 12 months 80
≥ 12 months 42
Number at risk
Successful 133
Unsuccessful 35
Successful PCI
Unsuccessful PCI
HR = 1.41 95% CI (0.42-4.18)
log-rank p = 0.41
Time (months)Time (months)
log-rank p = 0.47
shown less impact on the success rate of PCI in CTO. In fact, To-
masello at al. showed no association between estimated occlu-
sion duration, or even IOD, and procedural success rate in the 
analysis of 303 patients with CTO,18 in agreement with the results 
of the present study, which showed that the occlusion duration 
should not be considered as determining factor for decision-
-making regarding intervention in CTO. 
The prognostic effect of PCI in CTO remains controversial and to 
date there is no published randomized study to elucidate this ques-
tion. Many nonrandomized studies have shown favorable results in 
the short and long-term prognosis for patients successfully sub-
mitted to PCI in CTO, when compared to those whose procedure 
was unsuccessful.14,17,23,24,29 Similarly, recent meta-analyses have 
shown that successful PCI in CTO is associated with lower rates of 
mortality, need for revascularization, and residual or recurrent an-
gina, with no difference in the AMI rate when compared to patients 
with procedural failure.12,30,31 However, the present study showed 
no difference in the late follow-up regarding the rate of combined 
events of death from any cause, AMI, or new TVR between patients 
who had successful PCI, when compared to those with procedural 
failure. Possible explanations for this divergent finding of literature 
are the observational and retrospective design of most previous 
studies, as well as of the present study, which may have introduced 
a selection bias, creating heterogeneous groups that may have ge-
nerated differences in prognosis after the intervention; the size of 
this study’s population may not have been enough to detect a sig-
nificant difference in the clinical event rate, even with a long-term 
follow-up; and finally, the use of different definitions of clinical 
outcomes between studies. 
Several angiographic variables were identified in previous stu-
dies as independent predictors of procedural failure, such as le-
sion with long occlusion segment, presence of calcif ication, 
tortuosity in the lesion segment, lateral branch at the occlusion 
site, blunt stump, small reference vessel diameter, multivessel di-
sease, and ostial location of the occlusion.17,18,23,32,33 The present 
study confirmed some of these variables (long occlusion segment, 
tortuosity in the lesion segment and presence of calcification). 
However, making comparisons of predictors among various stu-
dies may be difficult, because most studies have a small number 
of patients and consequently little statistical power to identify 
independent predictors. Moreover, the duration definition for 
CTO shows significant difference between studies, ranging from 2 
weeks to 3 months as a criterion to define CTO. Furthermore, 
many studies showed incomplete angiographic data, with diffe-
rent definitions for lesion characteristics and inclusion of patients 
with TIMI grade 1 flow in the analyses.
Limitations
The present study has some limitations, as follows: first, its non-
randomized and retrospective study design may have introduced a 
selection bias; second, the results reflected the experience of a sin-
gle center, with intermediate-volume CTO operators; third, the low 
rate of the retrograde technique use, which is associated with higher 
success rates, may also have affected the results; and finally, due to 
the small sample size, this study did not have enough statistical 
power to draw conclusions on the rate of clinical events between the 
assessed groups and thus, the findings are considered only as hypo-
thesis generator.
Conclusions
Occlusion duration was associated with neither increased failure 
rate of the procedure nor worse late outcomes in patients submitted 
to percutaneous coronary intervention in chronically occluded coro-
nary arteries. Therefore, occlusion duration should not limit the the-
rapeutic approach in patients with chronic total occlusions.
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Figure 2. Cumulative rate curves of major adverse cardiovascular events (MACE) between the groups, according to the estimated occlusion duration (A) and failure or success in 
the procedure (B). PCI: percutaneous coronary intervention; HR: hazard ratio.
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